Back

The applicability of finerenone therapy across the broad spectrum of cardiovascular-kidney-metabolic syndrome: shaken not stirred

18 May 2025 (13:00 - 13:45)
Organised by: Logo
Congress Presentation Part of: Guideline recommended treatment in acute heart failure Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Balazs Muk

Gottsegen National Cardiovascular Center, Budapest (Hungary)

5 More presentations in this session

Presentation thumbnail
Up-titration of mineralocorticoid receptor antagonists across the ejection fraction spectrum following hospitalization for acute heart failure
Doctor G. Filiberti (Rozzano, IT)
Abstract Slides Video
Presentation thumbnail
A reason for optimism: opportunities for early initiation of evidence-based therapy in patients with acute heart failure
Assistant Professor V. Medovchshikov (Aktobe, KZ)
Abstract Slides Video
Presentation thumbnail
Feasebility and limitations of early and accelerated therapy following acute decompensated heart failure
Doctor G. Marino (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Mineralocorticoid receptor antagonists dose across the ejection fraction spectrum during hospitalization for acute heart failure
Doctor A. Giaj Levra (Rozzano, IT)
Abstract Slides Video
Presentation thumbnail
Use of non-diuretic pharmacological heart failure therapies in advanced heart failure patients with persistent congestion treated with sustained low-efficiency dialysis
Doctor T. Furlan (Trbovlje, SI)
Abstract Slides Video

Access the full session

Session thumbnail
Guideline recommended treatment in acute heart failure

The Event

Event poster

Heart Failure 2025

18 May 2025 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Deep dive and Q&A: unraveling the differences between MRAs for the treatment of heart and kidney disease. Join a conversation discussing key evidence!
thumbnail
Congress Presentation
Non-steroidal mineralocorticoid receptor antagonists (nsMRAs) in heart failure with mid-range and preserved ejection fraction: establishing a new standard in heart failure care
thumbnail
Congress Presentation
Maintaining momentum: optimizing finerenone use in heart and kidney disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources